Following this activity, participants should be able to: (1) Describe the prevalence of ESR1 and RET-fusion mutations in locally advanced and metastatic breast cancer; (2) Illustrate the role of targeted agents for ESR1 and RET-fusion mutations in the setting of locally advanced or metastatic breast cancer; and (3) Discuss key patient counseling and monitoring considerations for the use of elacestrant and selpercatinib in locally advanced or metastatic breast cancer.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96048
- Start Date: 2024-11-01 05:00:00
- End Date: 2024-11-01 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Menarini-Stemline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest